About us
Team
The team brings highly relevant experience including expertise in PIM kinase biology, immune regulation, medicinal chemistry and drug development complemented by extensive track record in fundraising and business development.
Simon Lowry
CEO
Experienced Physician Scientist with over 28 years of experience in clinical medicine and in the development of small molecule and biologic products. He is a graduate of Cambridge University School of Clinical Medicine and worked in internal medicine in the UK and in Australia before joining industry. He has held senior development and medical affairs roles in several large pharmaceutical companies including global development leader for pain and inflammation and medical affairs leader for oncology at Pfizer Inc, global medical affairs leader for immunology for Novartis, and CMO North America at Sun Pharma. He has held CMO roles in a number of biotech companies, including Immunovant, Kinevant Sciences and Zenas Biopharma. He has extensive experience in the development and commercialization of immuno-therapeutics and small molecule kinase inhibitors.
Stefan Haak
co-Founder and SVP R&D
Immunologist (PhD) with 15+ years of relevant scientific and business expertise in academic and industrial settings. Strong domain expertise in autoimmunity, inflammation & tissue immunity and immune oncology. Focus on innovation, preclinical drug discovery and translational research. “Serial Innovator”, initiated, led, and executed several novel drug discovery programs. Stefan served as Principal Investigator at the Technical University of Munich (TUM & HMGU) and as Biology Lead at Pieris Pharmaceuticals.
Marta Piquero Marti
co-Founder and Director Pre-clinical and Clinical Operations
PhD in Medicinal Chemistry and MsC in Drug Discovery. Over 8 years of drug discovery research experience developing novel therapeutic modalities in the fields of oncology, CNS, and infectious diseases. Prior to joining Mysthera, Marta worked as a Postdoctoral research associate at the University of Basel developing novel protein degraders with new mechanism of action. Marta served as Board member of the EFMC-YSN (European Federation of Medicinal Chemistry- Young Scientist Network).